Papers/PMID:23895820
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).
American heart journal2013The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
calciol — increases serum 25-hydroxyvitamin D concentration
Evidence strength: very limited.Findingreplicated ×33“The geometric mean (95% CI) of 25-hydroxyvitamin D3 increased from 48 nmol/L (43-54) at baseline to 80 nmol/L (75-87) after 6 weeks in the VitD3 treatment group and decreased from 47 nmol/L (42-53) to 44 nmol/L (39-49) in the control group (P < .001).”
Quoted verbatim from Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 2,000 IU oral VitD3 daily for 6 weeks
- Population
- Patients with stable chronic heart failure and reduced left ventricular ejection fraction; open-label, blinded end point trial; control group received no vitamin D3
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial).2013PMID:2389582010.1016/j.ahj.2013.05.009Permalink